

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 26, 2007

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 26, 2007, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its third fiscal quarter ending June 30, 2007. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
 - Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, for the first nine months of fiscal year 2006 after excluding the impact of insurance settlements occurring during the period. These settlements caused reported selling and administrative expense to be lower than it otherwise would have been for the period, although these settlements are not considered part of ordinary operations by management. Accordingly, we believe that measures of selling and administrative expense that are adjusted for the effects of these settlements are more indicative of BD’s underlying performance and assist investors in comparing BD’s selling and administrative expense for the period to other periods.
 - Operating Income. We present BD’s operating income, both alone and as a percentage of revenues, for the third quarter of fiscal year 2007 after excluding the impact of the in-process research and development (“R&D”) charge relating to our acquisition of Plasso Technology, Ltd (“Plasso”), and for the first nine months of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to the Plasso acquisition and our acquisition of TriPath Imaging, Inc. (“TriPath”). We also present these measures for the first nine months of fiscal year 2006 after excluding the impact of the previously mentioned insurance settlements and the impact of the in-process R&D charge relating to the acquisition of GeneOhm Sciences Inc. (“GeneOhm”). These items affected reported operating income for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD’s underlying performance, and also allow investors to better understand BD’s comparative operating performance for the period presented.
 - Income Taxes/Effective Tax Rate. We present income taxes and effective tax rate for the first nine months of fiscal year 2006 after excluding the impact of the previously mentioned insurance settlements. These settlements caused our reported income tax expense and effective tax rate for the period to be higher than they otherwise would have been, although these settlements are not considered part of ordinary operations by management. Management believes that these adjusted measures of income taxes are
-

more indicative of BD's underlying results, and also allow investors to better understand BD's comparative income tax expense and tax rate for the period.

- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for the third quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the Plasso acquisition, and for the first nine months of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to the Plasso and TriPath acquisitions, respectively. We also present BD's income from continuing operations, both alone and as a percentage of revenues, for the first nine months of fiscal year 2006 after excluding the impact of insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported income from continuing operations for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative income from continuing operations for the period presented.
- Earnings Per Share. We present earnings per share from continuing operations for the third quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the Plasso acquisition. We also present earnings per share from continuing operations for the first nine months of fiscal year 2007 (and projected earnings per share from continuing operations for fiscal year 2007) after excluding the impact of the in-process R&D charges relating to the Plasso and TriPath acquisitions, respectively. These charges caused (or will cause) reported earnings per share for the period presented to be lower than it otherwise would have been, although the charge is not considered by management to be part of ordinary operations. We believe that measures of earnings per share that are adjusted for the impact of these charges are more indicative of BD's underlying performance and also allow investors to more easily compare BD's results for these periods to other periods.

We also present earnings per share from continuing operations for the first nine months of fiscal year 2006 and the full 2006 fiscal year after excluding the impact of previously mentioned insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported earnings per share for these periods, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of earnings per share are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative performance for the period presented.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results

provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated July 26, 2007, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: July 26, 2007

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1

Press release dated July 26, 2007, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER

- Reports third-quarter earnings per share from continuing operations of 95 cents, an increase of 14% from the prior year's quarter
- Raises guidance for full fiscal year 2007 earnings per share from continuing operations to \$3.81 to \$3.83 from \$3.76 to \$3.80, excluding specified items

Franklin Lakes, NJ (July 26, 2007) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.631 billion for the third fiscal quarter ended June 30, 2007, representing an increase of 12 percent over the prior year period. This quarter's growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 3 percentage points of the increase in quarterly revenues.

“We are pleased with our strong results this quarter, with each of our three segments contributing to our growth,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “The combination of solid revenue growth and continued margin improvement is allowing us to increase our investment in innovation while at the same time driving double-digit increases in earnings. These results, along with our expectations for the remainder of fiscal 2007, have enabled us to once again increase our earnings outlook for the year.”

Analysis of Third Quarter and Nine-Month Periods of Fiscal Year 2007 and 2006 Earnings

Reported diluted earnings per share from continuing operations were 95 cents for the third quarter of fiscal 2007. The following analysis (Table 1) of diluted earnings per share from continuing operations for the third quarters of fiscal 2007 and 2006 identifies specified items that affect comparability of results between periods. As illustrated, third quarter fiscal 2007 diluted earnings per share from continuing operations of 98 cents, which exclude a specified item, increased by 18 percent over comparable third quarter fiscal 2006 diluted earnings per share from continuing operations of 83 cents. For the nine-month periods, diluted earnings per share from continuing operations of \$2.86 for fiscal 2007, which exclude specified items, increased by 14 percent over comparable fiscal 2006 diluted earnings per share from continuing operations of \$2.50, which exclude specified items.

(Table 1)

	Three Months Ended June 30,			Nine Months Ended June 30,		
	FY2007	FY2006	% Change	FY2007	FY2006	% Change
Diluted EPS from Continuing Operations:	\$ 0.95	\$ 0.83	14%	\$ 2.38	\$ 2.33	2%
Specified Items:						
In-Process Research and Development Charge	0.03 (1)	-		0.48 (2)	0.21 (2)	
Insurance Settlement	-	-		-	(0.04) (3)	
	0.03	-		0.48	0.17	
Diluted EPS from Continuing Operations						
Excluding Specified Items:	<u>\$ 0.98</u>	<u>\$ 0.83</u>	<u>18%</u>	<u>\$ 2.86</u>	<u>\$ 2.50</u>	<u>14%</u>

(1) Represents the effect on diluted earnings per share from continuing operations of an in-process research and development (“IPR&D”) charge recorded in the third quarter of fiscal 2007 related to the acquisition of Plasso Technology, Ltd. on May 4, 2007 for approximately \$10 million.

(2) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

(3) Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Company’s previously owned latex glove business.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$882 million, representing an increase of 10 percent from the prior year period. For the nine-month period ended June 30, 2007, the BD Medical segment reported 10 percent revenue growth. Strong sales in the Pharmaceutical Systems unit continued to significantly contribute to the growth of the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$492 million, representing an increase of 15 percent from the prior year’s quarter. This growth includes \$27 million of revenues from TriPath, which was acquired at the end of the first quarter of fiscal 2007. The Preanalytical Systems unit of the segment reported revenue growth of 9 percent. Third quarter revenues in the Diagnostic Systems unit of the segment increased 23 percent, again including revenues from the TriPath acquisition. For the nine-month period ended June 30, 2007, the BD Diagnostics segment reported 9 percent revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were \$258 million, representing an increase of 13 percent from the prior year’s quarter. Flow cytometry instrument and reagent sales, as well as sales of advanced bioprocessing products, contributed to growth. For the nine-month period ended June 30, 2007, the BD Biosciences segment reported 12 percent revenue growth, resulting from continued strong sales of those same products.

Geographic Results

Third quarter revenues in the U.S. were \$768 million, representing an increase of 10 percent over the prior year period, and include \$27 million of revenues from TriPath. Revenues outside the U.S. were \$863 million, representing an increase of 13 percent over the prior year period. Approximately 6 percentage points of the increase in international revenues resulted from the favorable impact of foreign currency translation.

For the nine-month period ended June 30, 2007, revenues in the U.S. were \$2.243 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were \$2.466 billion, representing an increase of 10 percent over the prior year period. Approximately 5 percentage points of the increase in international revenues relate to the favorable impact from foreign currency translation.

Fiscal 2007 Outlook for Full Year

The following analysis (Table 2) of estimated diluted earnings per share from continuing operations for the full fiscal year identifies specified items that affect the comparability of results between periods. As illustrated, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, for the full fiscal year 2007 will be in the \$3.81 to \$3.83 range, representing an increase of approximately 14 to 15 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.34 for the fiscal year 2006.

(Table 2)

	Twelve Months Ended		
	September 30,		
	<u>FY2007</u>	<u>FY2006</u>	<u>% Change</u>
	(Estimated)		
Diluted EPS from Continuing Operations:	\$3.33-\$3.35	\$ 3.18	5%
Specified Items:			
In-Process Research and Development Charge ⁽¹⁾	0.48	0.21	
Insurance Settlement ⁽²⁾	-	(0.04)	
Rounding	-	(0.01)	
	<u>0.48</u>	<u>0.16</u>	
Diluted EPS from Continuing Operations			
Excluding Specified Items:	<u>\$3.81-\$3.83</u>	<u>\$ 3.34</u>	<u>14%-15%</u>

(1) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

(2) Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Company's previously owned latex glove business.

Conference Call Information

A conference call regarding BD's third fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, July 26, 2007. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international), using access code 879048, through the close of business on Thursday, August 2, 2007.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life

science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2007 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Three Months Ended June 30,		
	2007	2006	% Change
REVENUES	\$ 1,631,159	\$ 1,457,347	11.9
Cost of products sold	791,071	719,515	9.9
Selling and administrative	412,164	374,565	10.0
Research and development	92,993	76,699	21.2
Acquired in-process research and development	7,394	-	NM
TOTAL OPERATING COSTS AND EXPENSES	1,303,622	1,170,779	11.3
OPERATING INCOME	327,537	286,568	14.3
Interest expense	(11,598)	(15,425)	(24.8)
Interest income	11,938	12,146	(1.7)
Other expense, net	1,774	(2,385)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	329,651	280,904	17.4
Income tax provision	89,182	69,834	27.7
INCOME FROM CONTINUING OPERATIONS	240,469	211,070	13.9
INCOME/(LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION/(BENEFIT) OF \$2,704 AND \$(2,865), RESPECTIVELY	4,340	(4,697)	NM
NET INCOME	\$ 244,809	\$ 206,373	18.6
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.98	\$ 0.86	14.0
Income/(loss) from discontinued operations	\$ 0.02	\$ (0.02)	NM
Net income	\$ 1.00	\$ 0.84	19.0
Diluted:			
Income from continuing operations	\$ 0.95	\$ 0.83	14.5
Income/(loss) from discontinued operations	\$ 0.02	\$ (0.02)	NM
Net income (1)	\$ 0.96	\$ 0.81	18.5
AVERAGE SHARES OUTSTANDING			
Basic	244,918	246,633	
Diluted	254,128	255,070	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2007		
	As Reported	Plasso IPR&D (1)	Excluding Item
Operating Income as a % of revenues	\$ 327,537 20.1%	\$ 7,394	\$ 334,931 20.5%
Income from continuing operations as a % of revenues	240,469 14.7%	7,394	247,863 15.2%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 0.95	\$ 0.03	\$ 0.98

(1) Represents the Acquired in-process research and development charge of \$7,394 related to the Plasso acquisition.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Nine Months Ended June 30,		
	2007	2006	% Change
REVENUES	\$ 4,708,607	\$ 4,275,401	10.1
Cost of products sold	2,264,544	2,084,227	8.7
Selling and administrative	1,202,879	1,069,914	12.4
Research and development	259,620	219,473	18.3
Acquired in-process research and development	122,133	53,300	NM
TOTAL OPERATING COSTS AND EXPENSES	3,849,176	3,426,914	12.3
OPERATING INCOME	859,431	848,487	1.3
Interest expense	(36,152)	(51,990)	(30.5)
Interest income	37,138	43,808	(15.2)
Other expense, net	5,278	(3,999)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	865,695	836,306	3.5
Income tax provision	258,636	238,076	8.6
INCOME FROM CONTINUING OPERATIONS	607,059	598,230	1.5
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION/(BENEFIT) OF \$14,066 AND \$(12,127), RESPECTIVELY	23,162	(19,929)	NM
NET INCOME	\$ 630,221	\$ 578,301	9.0
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.47	\$ 2.42	2.1
Income (loss) from discontinued operations	\$ 0.09	\$ (0.08)	NM
Net income (1)	\$ 2.57	\$ 2.34	9.8
Diluted:			
Income from continuing operations	\$ 2.38	\$ 2.33	2.1
Income (loss) from discontinued operations	\$ 0.09	\$ (0.08)	NM
Net income	\$ 2.47	\$ 2.25	9.8
AVERAGE SHARES OUTSTANDING			
Basic	245,296	247,588	
Diluted	255,129	256,500	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2007			
	As Reported	TriPath IPR&D (1)	Plasso IPR&D (1)	Excluding Items
Operating Income as a % of revenues	\$ 859,431 18.3%	\$ 114,739	\$ 7,394	\$ 981,564 20.8%
Income from continuing operations as a % of revenues	607,059 12.9%	114,739	7,394	729,192 15.5%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 2.38	\$ 0.45	\$ 0.03	\$ 2.86

(1) Represents the Acquired in-process research and development charges of \$114,739 and \$7,394 related to the TriPath and Plasso acquisitions, respectively.

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative as a % of revenues	\$ 1,069,914 25.0%	\$ 17,000	\$ -	\$ 1,086,914 25.4%
Operating Income as a % of revenues	848,487 19.8%	(17,000)	53,300	884,787 20.7%
Income taxes effective tax rate	238,076 28.5%	(6,460)	-	231,616 26.5%
Income from continuing operations as a % of revenues	598,230 14.0%	(10,540)	53,300	640,990 15.0%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 2.33	\$ (0.04)	\$ 0.21	\$ 2.50

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the Acquired in-process research and development charge of \$53,300 related to the GeneOhm acquisition.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended June 30,		
	2007	2006	% Change
<u>BD MEDICAL</u>			
United States	\$ 385,546	\$ 359,146	7.4
International	496,440	442,972	12.1
TOTAL	\$ 881,986	\$ 802,118	10.0
<u>BD DIAGNOSTICS</u>			
United States	\$ 272,946	\$ 233,428	16.9
International	218,579	193,511	13.0
TOTAL	\$ 491,525	\$ 426,939	15.1
<u>BD BIOSCIENCES</u>			
United States	\$ 109,593	\$ 102,547	6.9
International	148,055	125,743	17.7
TOTAL	\$ 257,648	228,290	12.9
<u>TOTAL REVENUES</u>			
United States	\$ 768,085	\$ 695,121	10.5
International	863,074	762,226	13.2
TOTAL	\$ 1,631,159	\$ 1,457,347	11.9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Nine Months Ended June 30,		
	2007	2006	% Change
BD MEDICAL			
United States	\$ 1,146,143	\$ 1,056,878	8.4
International	1,406,233	1,265,953	11.1
TOTAL	\$ 2,552,376	\$ 2,322,831	9.9
BD DIAGNOSTICS			
United States	\$ 781,644	\$ 686,728	13.8
International	625,512	599,497	4.3
TOTAL	\$ 1,407,156	\$ 1,286,225	9.4
BD BIOSCIENCES			
United States	\$ 314,942	\$ 291,878	7.9
International	434,133	374,467	15.9
TOTAL	\$ 749,075	\$ 666,345	12.4
TOTAL REVENUES			
United States	\$ 2,242,729	\$ 2,035,484	10.2
International	2,465,878	2,239,917	10.1
TOTAL	\$ 4,708,607	\$ 4,275,401	10.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 238,360	\$ 230,123	3.6
Diabetes Care	92,116	88,548	4.0
Pharmaceutical Systems	48,692	34,612	40.7
Ophthalmic Systems	6,378	5,863	8.8
TOTAL	\$ 385,546	\$ 359,146	7.4
BD DIAGNOSTICS			
Preanalytical Systems	\$ 139,572	\$ 131,909	5.8
Diagnostic Systems	133,374	101,519	31.4
TOTAL	\$ 272,946	\$ 233,428	16.9
BD BIOSCIENCES			
Discovery Labware	\$ 37,907	\$ 35,665	6.3
Immunocytometry Systems	51,234	47,027	8.9
Pharmingen	20,452	19,855	3.0
TOTAL	\$ 109,593	\$ 102,547	6.9
TOTAL UNITED STATES	\$ 768,085	\$ 695,121	10.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2007	2006	Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 233,835	\$ 217,993	7.3	1.6	5.7
Diabetes Care	82,754	75,193	10.1	4.3	5.8
Pharmaceutical Systems	168,057	139,468	20.5	12.6	7.9
Ophthalmic Systems	11,794	10,318	14.3	7.0	7.3
TOTAL	\$ 496,440	\$ 442,972	12.1	5.7	6.4
BD DIAGNOSTICS					
Preanalytical Systems	\$ 121,761	\$ 107,589	13.2	6.8	6.4
Diagnostic Systems	96,818	85,922	12.7	7.7	5.0
TOTAL	\$ 218,579	\$ 193,511	13.0	7.2	5.8
BD BIOSCIENCES					
Discovery Labware	\$ 32,561	\$ 29,356	10.9	6.1	4.8
Immunocytometry Systems	93,331	76,947	21.3	15.5	5.8
Pharminggen	22,163	19,440	14.0	8.0	6.0
TOTAL	\$ 148,055	\$ 125,743	17.7	12.2	5.5
TOTAL INTERNATIONAL	\$ 863,074	\$ 762,226	13.2	7.1	6.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2007	2006	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 472,195	\$ 448,116	5.4	2.6	2.8
Diabetes Care	174,870	163,741	6.8	4.2	2.6
Pharmaceutical Systems	216,749	174,080	24.5	18.2	6.3
Ophthalmic Systems	18,172	16,181	12.3	7.6	4.7
TOTAL	\$ 881,986	802,118	10.0	6.4	3.6
BD DIAGNOSTICS					
Preanalytical Systems	\$ 261,333	\$ 239,498	9.1	6.2	2.9
Diagnostic Systems	230,192	187,441	22.8	20.5	2.3
TOTAL	\$ 491,525	426,939	15.1	12.5	2.6
BD BIOSCIENCES					
Discovery Labware	\$ 70,468	\$ 65,021	8.4	6.2	2.2
Immunocytometry Systems	144,565	123,974	16.6	13.0	3.6
Pharmingén	42,615	39,295	8.4	5.5	2.9
TOTAL	\$ 257,648	228,290	12.9	9.8	3.1
TOTAL REVENUES	\$ 1,631,159	\$ 1,457,347	11.9	8.7	3.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 711,545	\$ 672,438	5.8
Diabetes Care	280,255	272,508	2.8
Pharmaceutical Systems	135,961	95,040	43.1
Ophthalmic Systems	18,382	16,892	8.8
TOTAL	\$ 1,146,143	\$ 1,056,878	8.4
BD DIAGNOSTICS			
Preanalytical Systems	\$ 403,211	\$ 380,110	6.1
Diagnostic Systems	378,433	306,618	23.4
TOTAL	\$ 781,644	\$ 686,728	13.8
BD BIOSCIENCES			
Discovery Labware	\$ 109,705	\$ 100,828	8.8
Immunocytometry Systems	146,684	133,691	9.7
Pharmingen	58,553	57,359	2.1
TOTAL	\$ 314,942	\$ 291,878	7.9
TOTAL UNITED STATES	\$ 2,242,729	\$ 2,035,484	10.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2007	2006	Reported	% Change	
				FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 675,741	\$ 628,421	7.5	3.0	4.5
Diabetes Care	234,491	217,899	7.6	2.9	4.7
Pharmaceutical Systems	462,540	389,912	18.6	11.5	7.1
Ophthalmic Systems	33,461	29,721	12.6	6.0	6.6
TOTAL	\$ 1,406,233	\$ 1,265,953	11.1	5.7	5.4
BD DIAGNOSTICS					
Preanalytical Systems	\$ 342,941	\$ 308,413	11.2	5.7	5.5
Diagnostic Systems	282,571	291,084	(2.9)	(6.4)	3.5
TOTAL	\$ 625,512	\$ 599,497	4.3	(0.2)	4.5
BD BIOSCIENCES					
Discovery Labware	\$ 94,987	\$ 87,279	8.8	4.8	4.0
Immunocytometry Systems	272,082	226,709	20.0	14.9	5.1
Pharmingen	67,064	60,479	10.9	6.2	4.7
TOTAL	\$ 434,133	\$ 374,467	15.9	11.1	4.8
TOTAL INTERNATIONAL	\$ 2,465,878	\$ 2,239,917	10.1	5.0	5.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2007	2006	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,387,286	\$ 1,300,859	6.6	4.5	2.1
Diabetes Care	514,746	490,407	5.0	2.9	2.1
Pharmaceutical Systems	598,501	484,952	23.4	17.7	5.7
Ophthalmic Systems	51,843	46,613	11.2	7.0	4.2
TOTAL	\$ 2,552,376	\$ 2,322,831	9.9	6.9	3.0
BD DIAGNOSTICS					
Preanalytical Systems	\$ 746,152	\$ 688,523	8.4	5.9	2.5
Diagnostic Systems	661,004	597,702	10.6	8.9	1.7
TOTAL	\$ 1,407,156	\$ 1,286,225	9.4	7.3	2.1
BD BIOSCIENCES					
Discovery Labware	\$ 204,692	\$ 188,107	8.8	7.0	1.8
Immunocytometry Systems	418,766	360,400	16.2	13.0	3.2
Pharmingen	125,617	117,838	6.6	4.2	2.4
TOTAL	\$ 749,075	\$ 666,345	12.4	9.7	2.7
TOTAL REVENUES	\$ 4,708,607	\$ 4,275,401	10.1	7.5	2.6